Background Almost 30 years after the first human implants, ICD therapy has become the
treatment of choice in patients at risk of developing malignant ventricular arrhythmias. 1, 2 …

The implantable cardioverter defibrillator (ICD) is able to reduce sudden arrhythmic death in
patients who are considered to be at high risk. However, the arrhythmic risk may be …

Background It is unknown whether implantable cardioverter-defibrillator (ICD) discharges
actively contribute to a worse prognosis independent of the underlying arrhythmia. There is …

Background The cost-effective use of implantable cardioverter-defibrillators (ICDs) for the
prevention of sudden cardiac death requires identification of patients at risk for ventricular …

Background The majority of sudden cardiac death (SCD) in patients with heart failure occurs
in those with mild‐moderate left ventricular (LV) systolic dysfunction (LVEF 36–50%) who …

Background Routine addition of an atrial lead during an implantable cardioverter‐
defibrillator (ICD) implantation for primary prevention of sudden cardiac death, in patients …

Background: Fast ventricular tachycardias (VTs) have historically been attributed to shorter
path lengths with smaller reentrant circuit dimensions in animal models. The relationship …

Despite the increasingly high rate of implantation of cardioverter-defibrillators (ICD) in
elderly patients, data supporting their clinical and cost-effectiveness in this age stratum are …

Background—The primary method for monitoring implantable cardioverter-defibrillator lead
integrity is periodic measurement of impedance. Sprint Fidelis leads are prone to pace …

Arrhythmias confer a substantial risk of mortality and morbidity in patients with heart failure
(HF), and this represents a major healthcare burden worldwide. There are at least 15 million …